Concepedia

Wendy Richmond

WR

Statistics

Publications

13

Citations

1.3K

H-Index

12

Active since

1987

Affiliations

Genomics Institute of the Novartis Research Foundation(Current)

Novartis (Switzerland)

Novartis (United States)

University of Basel

Swiss Tropical and Public Health Institute

Wendy Richmond is an author at Genomics Institute of the Novartis Research Foundation specializing in drug discovery, pharmacology, and medicinal chemistry.

Publications per year

1987–2022

13

Publications

13

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

Thomas H. Marsilje, Wei Pei, Bei Chen et al. · Journal of Medicinal Chemistry · 2013 · 412 citations · Full text

, , +16

Imaging of <i>Plasmodium</i> Liver Stages to Drive Next-Generation Antimalarial Drug Discovery

Stephan Meister, David Plouffe, Kelli Kuhen et al. · Science · 2011 · 347 citations · Full text

, , +16

Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases

A. S. Nagle, Agnes Biggart, C. Be et al. · Journal of Medicinal Chemistry · 2020 · 117 citations · Full text

, , +14

Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis

D. CHIANELLI, Paul V. Rucker, Jason Roland et al. · Journal of Medicinal Chemistry · 2020 · 99 citations · Full text

, , +16

Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 1

Ha-Soon Choi, Zhicheng Wang, Wendy Richmond et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 66 citations · Full text

, , +12

1–5 of 13